Helio Liver

About Helio Genomics

Helio Genomics is a private, pre-revenue diagnostics company pioneering a liquid biopsy platform for early cancer detection. Founded in 2015, the company combines genomic analysis of cell-free DNA with proprietary artificial intelligence algorithms to identify cancer-associated methylation patterns from a standard blood sample. Its lead program is focused on liver cancer (HCC), with the goal of addressing a significant unmet need in high-risk populations. The company's success hinges on clinical validation, regulatory approval, and demonstrating that its test can improve patient outcomes and be cost-effective within healthcare systems.

Therapeutic Areas